MedPath

AFT Pharmaceuticals Enters Late-Stage R&D for Novel Injectable

• AFT Pharmaceuticals has partnered with two European entities to advance a novel injectable medicine through late-stage research and development. • The agreement includes a Phase III clinical trial involving approximately 1,000 patients to confirm the medicine's efficacy and safety. • AFT will share the clinical trial costs and will participate in profits from sales and out-licensing activities globally, pending successful trials and commercialization. • The novel injectable targets a global market projected to grow from $3 billion in 2024 to over $7 billion by 2033, offering a single-dose advantage over existing treatments.

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) has announced a collaborative agreement with two European partners to finalize the research and development of a novel injectable medicine. This injectable features a patented New Chemical Entity (NCE). The partnership aims to conduct a confirmatory Phase III clinical trial involving approximately 1,000 patients to rigorously assess the medicine's efficacy and safety profile.
The agreement stipulates that AFT will equally share the costs of the Phase III trial with one of its European partners. Upon successful completion of the trial and subsequent commercialization, AFT is set to receive a share of the profits from all territories where the medicine is sold, as well as income derived from out-licensing activities. The partners anticipate launching the medicine within three years, with potential revenue from out-licensing preceding on-market sales.
The specific condition treated by the medicine remains confidential. However, it is designed for a global market anticipated to expand from approximately US$3 billion in 2024 to over US$7 billion by 2033. The injectable is administered as a single dose for most patients, potentially offering a significant advantage over current treatments that typically require two injections.
One of the partners has already developed the product to its current stage. AFT and the remaining partner will collaborate to complete the development, registration, and commercialization processes worldwide. The involved partners have requested that their identities remain confidential.
AFT Managing Director and CEO Hartley Atkinson commented, “This is an exciting project that offers us rapid entry into a highly attractive and significant global market. It also rounds out our research and development pipeline, which now positions the company well to significantly build on our enduring record of consistent long-term growth.”
The agreement is contingent upon the partners achieving a satisfactory meeting with both the European Medicines Agency (EMA) and the US FDA before March 31, 2025. It also requires final confirmation of Freedom to Operate for the manufacturing operation responsible for producing the medicine. AFT has committed to providing updates to the market as these conditions are met.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Affinia Therapeutics Advances AFTX-201 for BAG3 Dilated Cardiomyopathy

Affinia Therapeutics nominates AFTX-201 as its development candidate for BAG3 dilated cardiomyopathy (DCM), a monogenic heart disease affecting over 70,000 individuals.
AFTX-201, a potential best-in-class gene therapy, aims to replenish the BAG3 protein in the heart, restoring cardiac structure and function via a one-time IV injection.

FDA Reviews Pfizer and Lilly's Tanezumab for Osteoarthritis Pain

The FDA has begun its review of tanezumab, a non-opioid painkiller developed by Pfizer and Eli Lilly, for treating chronic pain associated with moderate-to-severe osteoarthritis.
Tanezumab, an NGF inhibitor, aims to provide relief for patients who do not respond adequately to other analgesic drugs, addressing a significant unmet need.

Pharmaessentia Corp. Advances with Phase III Clinical Trial for P1101 Targeting Pre-fibrotic/Early PMF

PharmaEssentia Corp. has submitted a Phase III clinical trial protocol for Ropeginterferon alfa-2b (P1101) to the China National Medical Products Administration, targeting adult patients with pre-fibrotic/early primary myelofibrosis or overt primary myelofibrosis at low or intermediate-1 risk.

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).
Crinecerfont is designed to reduce elevated androgen levels in individuals with CAH, addressing a critical unmet need in current treatment.

Daiichi Sankyo's Vanflyta Enters Phase 3 Trial for FLT3-ITD Negative AML

Daiichi Sankyo initiates the QuANTUM-Wild phase 3 trial to evaluate Vanflyta (quizartinib) in FLT3-ITD negative acute myeloid leukemia (AML).
The trial will assess Vanflyta combined with chemotherapy and as maintenance monotherapy for newly diagnosed AML patients.

Biofrontera's Ameluz Demonstrates Success in Phase III sBCC Trial, Stock Surges

Biofrontera's Ameluz-PDT therapy met the primary endpoint in a Phase III trial for superficial basal cell carcinoma (sBCC), showing significant clinical and histological clearance.
The Ameluz-PDT treatment achieved a 65.5% success rate compared to 4.8% in the placebo group, marking a substantial improvement in sBCC lesion clearance.

MaaT Pharma Completes Enrollment in Phase 3 Trial of MaaT013 for Acute Graft-versus-Host Disease

MaaT Pharma has completed recruitment for its Phase 3 ARES trial evaluating MaaT013 in patients with steroid and ruxolitinib-refractory acute Graft-versus-Host Disease.
The ARES trial is a multicenter, European, open-label, single-arm study assessing the safety and efficacy of MaaT013, with topline results expected in January 2025.

Melt Pharmaceuticals Completes Phase 3 Trial of MELT-300 for Cataract Surgery Sedation

Melt Pharmaceuticals has completed dosing in its Phase 3 trial of MELT-300, a non-IV, non-opioid sublingual tablet for procedural sedation during cataract surgery.
The trial is a randomized, double-blind study comparing MELT-300 to sublingual midazolam and placebo, with topline results expected by the end of 2024.

Bicara, Zenas, and MBX Bio Launch IPOs, Raising $703M for Clinical Trials

Bicara Therapeutics raised $315 million to fund a pivotal trial of ficerafusp alfa for head and neck squamous cell carcinoma (HNSCC).
Zenas Biopharma secured $225 million to advance obexelimab, a bifunctional antibody, through Phase 3 trials for IgG4-related disease and Phase 2 trials for multiple sclerosis, lupus, and wAIHA.

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

NTX-001, a drug-device combination by Neuraptive Therapeutics, has received Breakthrough Therapy Designation from the FDA for treating peripheral nerve injuries requiring repair.
The designation was granted based on promising Phase 2 NEUROFUSE study results, potentially accelerating NTX-001's development and review process.

Reference News

[1]
AFT enters late-stage R&D agreement for a novel injectable - NZX
nzx.com · Oct 20, 2024

AFT Pharmaceuticals enters late-stage R&D agreement with European partners for a novel injectable medicine, aiming to co...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy